Real-world safety and efficacy of risankizumab in psoriatic patients: a multicenter, retrospective, and not-interventional study

CONCLUSIONS: Risankizumab proved to be a safe and effective therapy for patients with moderate-to-severe psoriasis in the routine clinical practice.PMID:38452889 | DOI:10.1016/j.ad.2024.02.030

Source: Actas Dermo-Sifiliograficas - March 7, 2024 Category: Dermatology Authors: A Martorell S Santos-Alarc ón A Sahuquillo-Torralba R Rivera-D íaz I Belinch ón-Romero D Ruiz-Genao A Romero-Mat é R Ruiz-Villaverde M Ferr án-Farrés F Gallardo-Hern ández M Almenara-Blasco J Alonso-Su árez Á González-Cantero E Mart ínez-Lorenz Source Type: research